CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Drug: LYC-30937-EC +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02872285
NCT02872285Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis

Lycera Corp.·interventional·Posted Aug 19, 2016·Updated Apr 10, 2019

In Brief

A Phase 2 clinical trial evaluating Drug: LYC-30937-EC and Placebo for Psoriasis. Completed, enrolled 33 participants across 7 sites.

Detailed Summary

The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 19, 2016
Enrollment StartDec 5, 2016
Primary CompletionJun 22, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.9 years ago

Interventions

Drug: LYC-30937-ECdrug

Placebodrug